Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Humana Inc. pages available for free this week:
- Income Statement
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Reportable Segments
- Common Stock Valuation Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Total Asset Turnover since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Humana Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Current ratio | ||||||
Quick ratio | ||||||
Cash ratio |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
- Current Ratio
- The current ratio demonstrates a gradual decline from 1.82 in 2019 to 1.52 in 2022, indicating a decrease in the company's short-term liquidity over this period. However, in 2023, there is a slight recovery to 1.59, suggesting some improvement in the company's ability to cover its current liabilities with current assets.
- Quick Ratio
- The quick ratio follows a consistent downward trend from 1.47 in 2019 to 1.20 in 2021 and remains stable at 1.20 in 2022. In 2023, a modest increase to 1.24 is observed. This trend implies a reduction in the more liquid assets available to meet immediate liabilities, though the small increase in the latest year indicates a partial reversal of this decline.
- Cash Ratio
- The cash ratio decreases from 1.37 in 2019 to 1.08 in 2021, suggesting a diminishing cushion of cash and cash equivalents to cover current liabilities. This ratio shows a minor improvement in 2022 and 2023, rising to 1.10 and 1.13 respectively, indicating a slight strengthening in cash liquidity.
Current Ratio
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Current assets | ||||||
Current liabilities | ||||||
Liquidity Ratio | ||||||
Current ratio1 | ||||||
Benchmarks | ||||||
Current Ratio, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Current Ratio, Sector | ||||||
Health Care Equipment & Services | ||||||
Current Ratio, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
- Current Assets
- Current assets showed a consistent upward trend over the five-year period, increasing from $19,888 million in 2019 to $29,986 million in 2023. This represents steady growth in the company's liquid assets available within one year.
- Current Liabilities
- Current liabilities also increased consistently, rising from $10,929 million in 2019 to $18,872 million in 2023. The growth in short-term obligations indicates an expansion in the company's immediate financial responsibilities.
- Current Ratio
- The current ratio declined from 1.82 in 2019 to a low of 1.52 in 2022, before slightly recovering to 1.59 in 2023. This downward trend suggests that, although current assets increased, current liabilities grew at a faster rate, somewhat reducing liquidity coverage over the period. The slight improvement in the most recent year may indicate a stabilization in short-term financial health.
Quick Ratio
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Cash and cash equivalents | ||||||
Investment securities | ||||||
Receivables, net of allowances | ||||||
Total quick assets | ||||||
Current liabilities | ||||||
Liquidity Ratio | ||||||
Quick ratio1 | ||||||
Benchmarks | ||||||
Quick Ratio, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Quick Ratio, Sector | ||||||
Health Care Equipment & Services | ||||||
Quick Ratio, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The presented financial data reveals several key trends over the five-year period ending in 2023. Total quick assets showed a consistent increase year over year, rising from $16,082 million in 2019 to $23,355 million in 2023. This indicates a steady improvement in liquid assets available to cover immediate liabilities.
Current liabilities also increased throughout the same period, growing from $10,929 million in 2019 to $18,872 million in 2023. The rising trend in current liabilities suggests that the company has been expanding its short-term obligations, possibly reflecting growth activities or increased operational costs.
The quick ratio, which measures the ability to meet short-term obligations with liquid assets, started at 1.47 in 2019 and decreased to 1.24 by 2023. Despite fluctuations, the quick ratio remained above 1.0 during the entire period, indicating that the company maintained adequate liquidity. However, the downward trend from 1.47 to around 1.2 over the years points to a relative decline in liquid assets compared to current liabilities, reflecting a slight tightening in short-term liquidity position.
Overall, the data demonstrates growth in both liquid assets and current liabilities, with liquidity remaining comfortable but gradually declining in proportional strength. This suggests that while liquid resources have expanded, short-term obligations have increased at a faster pace, requiring careful monitoring of liquidity management going forward.
Cash Ratio
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Cash and cash equivalents | ||||||
Investment securities | ||||||
Total cash assets | ||||||
Current liabilities | ||||||
Liquidity Ratio | ||||||
Cash ratio1 | ||||||
Benchmarks | ||||||
Cash Ratio, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Cash Ratio, Sector | ||||||
Health Care Equipment & Services | ||||||
Cash Ratio, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
1 2023 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
- Total cash assets
- The total cash assets demonstrate a generally increasing trend from 2019 through 2023. Starting at $15,026 million in 2019, the amount rose to $21,320 million in 2023. There was a slight dip observed in 2021, where cash assets decreased from $17,227 million in 2020 to $16,586 million, followed by a recovery in subsequent years.
- Current liabilities
- Current liabilities have shown a continuous upward trend over the period, increasing each year from $10,929 million in 2019 to $18,872 million in 2023. This consistent growth indicates a rising level of short-term obligations relative to prior years.
- Cash ratio
- The cash ratio exhibited a decreasing trend from 1.37 in 2019 to 1.08 in 2021, reflecting a decline in available liquid assets relative to current liabilities over the initial years. However, the ratio stabilized and showed marginal increases in 2022 and 2023, ending at 1.13. Despite these improvements, the cash ratio remains lower than the 2019 level, suggesting tighter liquidity conditions compared to the beginning of the period.